Irritable Bowel Syndrome Clinical Trial
— ZelfHyOfficial title:
Hypnotherapy Through Self-exercises in Children With Functional Abdominal Pain in Primary Care
Verified date | May 2024 |
Source | University Medical Center Groningen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this randomised controlled trial is to study the (cost-)effectiveness of home-based hypnotherapy by self-exercises in children with functional abdominal pain (FAP) or irritable bowel syndrome (IBS) in primary care. The main questions it aims to answer are: - What is the effect of home-based hypnotherapy by self-exercises on adequate relief of abdominal pain and discomfort in addition to care as usual of general practitioners (GPs), compared to care as usual of GPs alone in children with FAP or IBS? - What is the effect of home-based hypnotherapy by self-exercises in addition to care as usual by GPs compared to care as usual of GPs alone in children with FAP or IBS on: - Frequency and intensity of abdominal pain and discomfort - Pain severity - Daily functioning and impact - Anxiety and depression - Pain beliefs - Sleep disturbances - School absence - Use of health care services, including GP visits and referrals to secondary care - Costs (healthcare and societal perspective) Participants in the intervention group will receive home-based hypnotherapy 5 times a week for approximately 15-20 minutes a day during 3 months in addition to care as usual by their GP according to the Dutch society of GPs' guideline for children with abdominal pain. Participants in the control group will receive care as usual by their GP according to the Dutch society of GPs' guideline for children with abdominal pain.
Status | Active, not recruiting |
Enrollment | 152 |
Est. completion date | April 1, 2025 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 17 Years |
Eligibility | Inclusion Criteria: - Aged 7 to 17 years - GP visit concerning chronic gastrointestinal symptoms - FAP or IBS according to their GP Exclusion Criteria: - A concomitant organic gastrointestinal disease - Treatment by a paediatrician for abdominal symptoms - Intellectual disability - A history of a psychotic disorder - Hypnotherapy treatment in the past year - Insufficient knowledge of the Dutch language by the child or parents |
Country | Name | City | State |
---|---|---|---|
Netherlands | University Medical Center Groningen | Groningen |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen | ZonMw: The Netherlands Organisation for Health Research and Development |
Netherlands,
Castarlenas E, Jensen MP, von Baeyer CL, Miro J. Psychometric Properties of the Numerical Rating Scale to Assess Self-Reported Pain Intensity in Children and Adolescents: A Systematic Review. Clin J Pain. 2017 Apr;33(4):376-383. doi: 10.1097/AJP.0000000000000406. — View Citation
Ebesutani C, Reise SP, Chorpita BF, Ale C, Regan J, Young J, Higa-McMillan C, Weisz JR. The Revised Child Anxiety and Depression Scale-Short Version: scale reduction via exploratory bifactor modeling of the broad anxiety factor. Psychol Assess. 2012 Dec;24(4):833-45. doi: 10.1037/a0027283. Epub 2012 Feb 13. — View Citation
Gieteling M, Van Dijk P, De Jonge A, Albeda F, Berger M, Burgers J. NHG-Standaard Buikpijn bij kinderen. Huisarts Wet 2012; 55: 404-409.
Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional Disorders: Children and Adolescents. Gastroenterology. 2016 Feb 15:S0016-5085(16)00181-5. doi: 10.1053/j.gastro.2016.02.015. Online ahead of print. — View Citation
iMTA Productivity Cost Questionnaire and iMTA Medical Consumption Questionnaire. Retrieved at the 9th of April 2020 from https://www.imta.nl/questionnaires/.
Lisman-van Leeuwen Y, Spee LA, Benninga MA, Bierma-Zeinstra SM, Berger MY. Prognosis of abdominal pain in children in primary care--a prospective cohort study. Ann Fam Med. 2013 May-Jun;11(3):238-44. doi: 10.1370/afm.1490. — View Citation
Mangel AW, Hahn BA, Heath AT, Northcutt AR, Kong S, Dukes GE, McSorley D. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res. 1998 Mar-Apr;26(2):76-81. doi: 10.1177/030006059802600203. — View Citation
Meesters C, Muris P, Ghys A, Reumerman T, Rooijmans M. The Children's Somatization Inventory: further evidence for its reliability and validity in a pediatric and a community sample of Dutch children and adolescents. J Pediatr Psychol. 2003 Sep;28(6):413-22. doi: 10.1093/jpepsy/jsg031. — View Citation
Ravens-Sieberer U, Gosch A, Rajmil L, Erhart M, Bruil J, Duer W, Auquier P, Power M, Abel T, Czemy L, Mazur J, Czimbalmos A, Tountas Y, Hagquist C, Kilroe J, Kidscreen Group E. KIDSCREEN-52 quality-of-life measure for children and adolescents. Expert Rev Pharmacoecon Outcomes Res. 2005 Jun;5(3):353-64. doi: 10.1586/14737167.5.3.353. — View Citation
Ravens-Sieberer U, Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, Egmar AC, Gusi N, Herdman M, Jelsma J, Kind P, Olivares PR, Scalone L, Greiner W. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Qual Life Res. 2010 Aug;19(6):887-97. doi: 10.1007/s11136-010-9649-x. Epub 2010 Apr 17. — View Citation
Rutten JM, Vlieger AM, Frankenhuis C, George EK, Groeneweg M, Norbruis OF, Tjon a Ten W, Van Wering H, Dijkgraaf MG, Merkus MP, Benninga MA. Gut-directed hypnotherapy in children with irritable bowel syndrome or functional abdominal pain (syndrome): a randomized controlled trial on self exercises at home using CD versus individual therapy by qualified therapists. BMC Pediatr. 2014 Jun 4;14:140. doi: 10.1186/1471-2431-14-140. — View Citation
Rutten JMTM, Vlieger AM, Frankenhuis C, George EK, Groeneweg M, Norbruis OF, Tjon A Ten W, van Wering HM, Dijkgraaf MGW, Merkus MP, Benninga MA. Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial. JAMA Pediatr. 2017 May 1;171(5):470-477. doi: 10.1001/jamapediatrics.2017.0091. — View Citation
Saps M, van Tilburg MA, Lavigne JV, Miranda A, Benninga MA, Taminiau JA, Di Lorenzo C. Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials. Neurogastroenterol Motil. 2016 Nov;28(11):1619-1631. doi: 10.1111/nmo.12896. Epub 2016 Jul 31. — View Citation
Steur LMH, Grootenhuis MA, Terwee CB, Pillen S, Wolters NGJ, Kaspers GJL, van Litsenburg RRL. Psychometric properties and norm scores of the sleep self report in Dutch children. Health Qual Life Outcomes. 2019 Jan 16;17(1):15. doi: 10.1186/s12955-018-1073-x. — View Citation
Stone AL, Walker LS, Laird KT, Shirkey KC, Smith CA. Pediatric Pain Beliefs Questionnaire: Psychometric Properties of the Short Form. J Pain. 2016 Sep;17(9):1036-44. doi: 10.1016/j.jpain.2016.06.006. Epub 2016 Jun 27. — View Citation
Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, Egmar AC, Greiner W, Gusi N, Herdman M, Jelsma J, Kind P, Scalone L, Ravens-Sieberer U. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010 Aug;19(6):875-86. doi: 10.1007/s11136-010-9648-y. Epub 2010 Apr 20. — View Citation
* Note: There are 16 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient baseline characteristics | Patient baseline characteristics will be collected from the GP's inclusion form / response card include gender, age/birthdate, and school level. Data on co-morbidities/medical history and medication use will be extracted from the child's medical records at the GP's practice after 12 months follow-up. | Baseline | |
Other | Paediatric gastrointestinal symptoms | Paediatric gastrointestinal symptoms at baseline are measured using the Dutch version of the Rome IV questionnaire. The Rome IV consists of a parent report, and a self-report for children aged 10 years and older. | Baseline | |
Other | Usage of hypnotherapy self-exercises | Data on the frequency and duration of the intervention use as well as the exercises selected will be obtained from the online website/portal for the IG only after the 3 months intervention period. | 3 months | |
Other | Treatment expectations | To evaluate placebo effects, one question will be incorporated at baseline about whether the child and parents (asked separately) expect that the symptoms will improve with the treatment on an 11-point scale (0 = not at all; 10 = complete recovery). They will also be asked whether they have a preference for the IG or the CG. | Baseline | |
Other | Quality of exercises | Each exercise will be rated with an overall score (range 0 - 10) as well as qualitatively by asking to fill out positives and negatives. This will be done after 3 months for the IG only. | 3 months | |
Other | Somatisation | Child and/or parents will evaluate the experienced somatic symptoms by scoring the Children's Somatization Inventory (CSI). The inventory consists of 35 items on physical symptoms with a scoring scale per item ranging from 0 (no problems at all) to 4 (a whole lot). A total score can be computed by summing the scores across all items, with higher scores indicating a higher intensity of functional complaints. The inventory has been translated into Dutch and has good psychometric properties. | 0, 3, 6, and 12 months | |
Primary | Adequate relief at 12 months | Proportion of children with adequate relief of abdominal pain at 12 months follow-up Child and/or parents are asked whether the child has adequate relief of FAP or IBS related abdominal pain during the past week using a dichotomous scale (yes/no). This question is a well validated outcome measurement in trials on treatment for IBS. | 12 months | |
Secondary | Adequate relief at 3 and 6 months | Proportion of children with adequate relief of abdominal pain at 3 and 6 months follow-up Child and/or parents are asked whether the child has adequate relief of FAP or IBS related abdominal pain during the past week using a dichotomous scale (yes/no). This question is a well validated outcome measurement in trials on treatment for IBS. | 3 and 6 months | |
Secondary | Pain frequency and intensity | Child and/or parents will assess the abdominal pain or discomfort during seven consecutive days with a diary at baseline and during follow-up. A score of seven days is totalled in a pain frequency score (range 0 tot 21) and a pain intensity score (range 0 to 21). A reduction in abdominal pain/discomfort is defined as at least 50% reduction in both scores. | 0, 3, 6, and 12 months | |
Secondary | Severity of pain | Child and/or parents will assess the severity of the abdominal pain or discomfort during the past week with a 0-10 numerical rating scale (NRS-11) at baseline and during follow-up. The NRS-11 is also integrated as outcome measure for pain/discomfort, because there is much heterogeneity between various pain scales. This scale measures pain severity, while the pain diary reports also frequency, intensity and duration of the pain and/or discomfort in order to complement each other. | 0, 3, 6, and 12 months | |
Secondary | Daily functioning and impact | Child and/or parents will assess the impact of the abdominal pain and discomfort on their daily functioning and quality of life with the KIDSCREEN-52. The KIDSCREEN-52 is a health-related quality of life questionnaire for children and adolescents. It includes 52 items covering ten dimensions of physical, psychologic and social aspects. The instrument has sound measurement properties and is available in Dutch. | 0, 3, 6, and 12 months | |
Secondary | Anxiety and depression | Child and/or parents will assess their mental well-being using the short version of the Revised Child Anxiety and Depression Scale (RCADS-25). Children will be asked to indicate how often each item (15 anxiety items and 10 depression items) applies to them according to a 4-point scale (never to always) at baseline and during follow-up. The validity and reliability for both subscales of this short version of the RCADS were acceptable and not significantly different from the extensive version of the RCADS. | 0, 3, 6, and 12 months | |
Secondary | Pain beliefs | Child and/or parents will score the pain beliefs with the paediatric Pain Beliefs Questionnaire (PBQ) at baseline and during follow-up. This questionnaire consists of 32 items scored on a 5-point Likert scale. | 0, 3, 6, and 12 months | |
Secondary | Sleep disturbances | Child and/or parents will evaluate sleep disturbances with three selected questions from the validated Sleep Self Report: 1) Do you fall asleep in about 20 minutes? 2) Do you wake up at night when your parents think you are asleep? 3) Do you feel sleepy during the day? Children will be asked to indicate the frequency of occurrence of these items in the past week in three categories: rarely (0-1 time per week), sometimes (2-4 times per week), and usually (5-7 times per week). | 0, 3, 6, and 12 months | |
Secondary | School absence | Parents will administer the missed days at school during the past 3 months prior to baseline and during follow-up. The question is integrated in the cost-questionnaire administered to parents. | 0, 3, 6, and 12 months | |
Secondary | Healthcare consumption | Medical records of the participating children will be screened at 12-months follow-up by the researcher/research assistant for the number of GP visits due to functional somatic symptoms and/or FAP or IBS; referrals due to FAP or IBS; and medication use over the past year. | 0, 3, 6, and 12 months | |
Secondary | Cost-effectiveness | The cost-effectiveness analysis will be based upon the iMTA instruments (productivity cost questionnaire and medical consumption questionnaire) to collect data regarding health care consumption and productivity losses. | 0, 3, 6, and 12 months | |
Secondary | Cost-utility | For the cost-utility analysis, child and/or parents will score the EuroQoL Youth (EQ-5D-Y), which is a generic measure for quality of life suitable for utility calculations. This instrument includes five items (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) and three levels of severity problems (no problems, some problems, a lot of problems). The questionnaire is feasible, reliable and valid, and developed for children aged 8 years and older. | 0, 3, 6, and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |